Japan has agreed to purchase 1.4 million COVID-19 vaccines
- Brief Intermittent Exercise Reduces Heart Disease and Death Risk
- Personalized Lung Tumor Chips Assess PD-1 Therapy Response
- Study Shows Prior Infection Offers Strong Immunity to Original COVID-19 Strain
- Chinese Food Products Dominate Korean Tables Amid Safety Concerns
- Early Detection of Hypopharyngeal Cancer Possible with Saliva Diagnosis
- EB Virus Could Be Infected by Kiss: A Hidden Threat Linked to Cancer
Japan has agreed to purchase 1.4 million COVID-19 vaccines
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Japan has agreed to purchase 1.4 million COVID-19 vaccines
The Japan government has agreed to purchase 1.4 million doses of the first domestically developed COVID-19 vaccine, “Daichirona Injectable,” from Daiichi Sankyo, with deliveries expected in early December.
On Nov 17th, the Ministry of Japan Health, Labour, and Welfare announced that it had reached an agreement to purchase 1.4 million doses of the COVID-19 vaccine, targeting all age groups, from Daiichi Sankyo to address the Omicron variant’s XBB sublineage.
This marks the first purchase agreement for a domestically developed vaccine by the country.
The announcement was made by Minister of Health, Labour, and Welfare, Keizo Takumi, in a press conference after the cabinet meeting on Nov 17th.
Daiichi Sankyo’s COVID-19 vaccine, approved for domestic manufacturing and sales for the first time in August, had not been utilized previously for the conventional virus strain. In September, the company reapplied for approval for an XBB-compatible vaccine.
If approval for the XBB-compatible vaccine is granted at the expert panel meeting on November 27th, distribution to local governments will commence from the week of December 4th.
Previously, the Ministry of Health, Labour, and Welfare had entered into purchase agreements for a total of 45 million doses of XBB-compatible vaccine from Pfizer and Moderna in preparation for the autumn vaccination campaign. While the autumn vaccination campaign targets all generations aged six months and above, local governments have been advised to prioritize vaccination for individuals aged 65 and above and those with underlying health conditions.
Japan has agreed to purchase 1.4 million COVID-19 vaccines
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.